Astri Therapeutics Inc (ATXS) Stock Price, Quote & News

Company Profile

Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatm...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 349 1971

Fax: 617 273 2637

Website: www.astriatx.com

Address:

22 Boston Wharf Road, 10th floor, Boston, United States

G101SPM Jan. 23 at 2:23 PM

$BCRX $6.74 Holding long position https://stocktwits.com/search/u/G101SPM?symbol=BCRX BRIEF: BioCryst Pharma completes acquisition of Astria Therapeutics ($ATXS) The transaction strengthens its position as a leader in hereditary angioedema and enhances the company's long-term growth trajectory. BioCryst adds navenibart, a late-stage, long-acting plasma kallikrein inhibitor currently in Phase 3 clinical development, to its HAE portfolio. The potential to be the first HAE therapy with every-three and every-six month dosing, combined with a high level of attack control, positions navenibart to significantly improve the treatment experience for HAE patients. BioCryst also obtains Astria's early-stage program for atopic dermatitis, STAR0310, for which the company plans to pursue strategic alternatives. The acquisition was completed for an implied transaction value of approximately $700 million.

0 · Reply

G101SPM Jan. 22 at 11:17 AM

$ATXS $12.50 bid Holding long position at $7.60 (net cost) https://stocktwits.com/G101SPM/message/602342237 BRIEF: Astria Therapeutics stockholders vote to approve acquisition by BioCryst ($BCRX); parties expect the Merger to close on or about January 23. 2026. note: Carrying long position of BCRX.

0 · Reply

ShortsHater Jan. 21 at 9:31 PM

$BCRX and $ATXS merger done, better days ahead

0 · Reply

Mergerbrief Jan. 21 at 1:09 PM

$ATXS / $BCRX – Shareholder Vote $ATXS MergerBrief.com M&A Tracking

0 · Reply

Night_Owl_Biotech Jan. 19 at 6:58 PM

Attached is a compilation of $BCRX & $ATXS operating forecasts as prepared by ATXS management. ATXS management projected BCRX revenues would peak in FY2030. ATXS projects 95% gross margins on Navenibart sales. At the bottom is a comparison of BCRX analyst estimates versus the total revenues forecast by ATXS management. This is for informational purposes only. This is not investment advice. $XBI $IBB $NBI

2 · Reply

TwongStocks Jan. 12 at 9:08 PM

$ATXS Equity Corporate Actions Alert #2026 - 13 Information Regarding the Merger of Astria Therapeutics, Inc. (ATXS) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-13 At a special meeting to be held on January 21, 2026, the shareholders of Astria Therapeutics, Inc. (ATXS) will vote on the proposed merger with BioCryst Pharmaceuticals, Inc. (BCRX). The merger is tentatively scheduled to close prior to the market open on January 23, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on January 22, 2026. If the merger closes as anticipated, the stock will remain halted on the day of closing (January 23rd) and will be suspended effective January 26, 2026.

0 · Reply

Lord_Monsoon Dec. 31 at 4:01 PM

$ATXS who’s holding for the sale next month? Current stock price is a 2 percent profit for me and I’ve been in since this was catb. It’s very tempting to sell and get out with some profit after all these years of reverse splits, failed studies, and takeovers.

1 · Reply

SuperGreenToday Dec. 5 at 10:31 AM

$ATXS Share Price: $13.10 Contract Selected: Apr 17, 2026 $10 Calls Buy Zone: $2.68 – $3.31 Target Zone: $4.29 – $5.24 Potential Upside: 51% ROI Time to Expiration: 132 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

RunnerSignals Dec. 3 at 5:34 PM

$ATXS $APA $GM $AMKR $CX Five different sectors, one story: strength on strength and Who got the real stamina? https://stocksrunner.com/news/2025-12-03-52-week-highs-surge-as-breakout-stocks-hit-fresh-peaks

0 · Reply

TwongStocks Dec. 3 at 12:07 PM

$BCRX Receives Early Termination of HSR Waiting Period for $ATXS Acquisition https://www.globenewswire.com/news-release/2025/12/03/3198739/29446/en/BioCryst-Receives-Early-Termination-of-HSR-Waiting-Period-for-Astria-Acquisition.html "Termination of the waiting period under the HSR Act satisfied one of the conditions for consummation of the Merger. BioCryst expects the Merger to close in the first quarter of 2026, subject to other customary closing conditions."

0 · Reply

Astria Stockholders Vote to Approve Acquisition by BioCryst

Nov 30, 2025, 1:29 AM EST - 2 months ago

Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold

Nov 12, 2025, 8:00 AM EST - 2 months ago

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Nov 6, 2025, 8:00 AM EST - 3 months ago

Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart

Oct 31, 2025, 8:00 AM EDT - 3 months ago

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Oct 17, 2025, 3:20 PM EDT - 3 months ago

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

BCRX

Oct 14, 2025, 12:20 PM EDT - 4 months ago

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'

BCRX

Oct 14, 2025, 7:35 AM EDT - 4 months ago

BioCryst to buy Astria Therapeutics in $700 million deal

BCRX

Oct 14, 2025, 7:00 AM EDT - 4 months ago

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

BCRX

Oct 9, 2025, 8:00 AM EDT - 4 months ago

Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting

Oct 8, 2025, 8:00 AM EDT - 4 months ago

Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema

Oct 3, 2025, 8:00 AM EDT - 4 months ago

Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA

Oct 2, 2025, 4:10 PM EDT - 4 months ago

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 2, 2025, 8:00 AM EDT - 4 months ago

Astria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT Trial

Sep 17, 2025, 8:00 AM EDT - 4 months ago

Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology

Sep 5, 2025, 2:07 AM EDT - 5 months ago

Astria Therapeutics, Inc. (ATXS) Presents at Cantor Global Healthcare Conference 2025 Transcript

Sep 3, 2025, 8:00 AM EDT - 5 months ago

Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025

Aug 27, 2025, 8:00 AM EDT - 5 months ago

Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference

Aug 12, 2025, 4:10 PM EDT - 6 months ago

Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 6, 2025, 8:00 AM EDT - 6 months ago

Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan

Jul 7, 2025, 8:00 AM EDT - 7 months ago

Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit

Jun 18, 2025, 8:00 AM EDT - 8 months ago

Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit

Jun 13, 2025, 7:00 AM EDT - 8 months ago

Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress

Jun 6, 2025, 8:00 AM EDT - 8 months ago

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress

May 28, 2025, 8:00 AM EDT - 8 months ago

Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference

May 23, 2025, 8:00 AM EDT - 9 months ago

Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop

May 22, 2025, 8:00 AM EDT - 9 months ago

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

May 13, 2025, 4:10 PM EDT - 9 months ago

Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 1, 2025, 8:00 AM EDT - 9 months ago

Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology

Apr 30, 2025, 8:00 AM EDT - 9 months ago

Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference

Mar 11, 2025, 8:00 AM EDT - 11 months ago

Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Feb 27, 2025, 8:00 AM EST - 1 year ago

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

Feb 25, 2025, 8:00 AM EST - 1 year ago

Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 8:00 AM EST - 1 year ago

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress

Feb 17, 2025, 10:32 PM EST - 1 year ago

Astria Therapeutics: A High-Conviction Bet On HAE

Feb 4, 2025, 8:00 AM EST - 1 year ago

Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 8:00 AM EST - 1 year ago

Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session

Jan 23, 2025, 8:00 AM EST - 1 year ago

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Jan 13, 2025, 8:00 AM EST - 1 year ago

Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

Dec 11, 2024, 8:00 AM EST - 1 year ago

Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

Dec 10, 2024, 8:00 AM EST - 1 year ago

Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Nov 27, 2024, 8:00 AM EST - 1 year ago

Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema

Nov 13, 2024, 4:10 PM EST - 1 year ago

Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Nov 13, 2024, 8:00 AM EST - 1 year ago

Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting

Oct 16, 2024, 8:00 AM EDT - 1 year ago

European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics' Investigational Therapy for the Treatment of Hereditary Angioedema

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema

G101SPM Jan. 23 at 2:23 PM

0 · Reply

G101SPM Jan. 22 at 11:17 AM

0 · Reply

ShortsHater Jan. 21 at 9:31 PM

$BCRX and $ATXS merger done, better days ahead

0 · Reply

Mergerbrief Jan. 21 at 1:09 PM

$ATXS / $BCRX – Shareholder Vote $ATXS MergerBrief.com M&A Tracking

0 · Reply

Night_Owl_Biotech Jan. 19 at 6:58 PM

2 · Reply

TwongStocks Jan. 12 at 9:08 PM

0 · Reply

Lord_Monsoon Dec. 31 at 4:01 PM

1 · Reply

SuperGreenToday Dec. 5 at 10:31 AM

0 · Reply

RunnerSignals Dec. 3 at 5:34 PM

0 · Reply

TwongStocks Dec. 3 at 12:07 PM

0 · Reply

Watson42 Dec. 1 at 4:34 PM

There is some resilience here. It just takes a buyout. $ACB $ATXS $MEDXF (Mutiny on the Bounty, Movie 1935)

0 · Reply

OpenOutcrier Nov. 12 at 9:01 PM

RECAP 11/12 Chatter: $NVA + DOD Contract $WULF + Anthropic Expansion RECAP 11/12 +Pos Comments: $NTAP + BWG RECAP 11/12 -Neg Comments: $ATXS - Cantor Live Breaking trading news www.openoutcrier.com

0 · Reply

JarvisFlow Nov. 12 at 7:06 PM

Cantor Fitzgerald has updated their rating for Astria Therapeutics ( $ATXS ) to Neutral.

0 · Reply

SNOB_ORDER Nov. 6 at 1:46 PM

$BCRX $ATXS Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart https://www.businesswire.com/news/home/20251106100618/en/Astria-Therapeutics-Announces-Final-Positive-Results-from-All-Enrolled-HAE-Patients-in-the-ALPHA-STAR-Phase-1b2-Trial-of-Navenibart

3 · Reply

DARKP00L Nov. 6 at 1:15 PM

$ATXS 08:14 on Nov. 06 2025 Astria Therapeutics ALPHA-STAR Phase 1b/2 Study Evaluating Navenibart Monoclonal Antibody Inhibitor In Hereditary Angioedema Participants Shows Robust Attack Rate Reduction, Favorable Safety, Tolerability Profile #tradeideas

0 · Reply

TwongStocks Nov. 6 at 1:01 PM

$ATXS Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart https://www.businesswire.com/news/home/20251106100618/en/Astria-Therapeutics-Announces-Final-Positive-Results-from-All-Enrolled-HAE-Patients-in-the-ALPHA-STAR-Phase-1b2-Trial-of-Navenibart

0 · Reply

Zackattack15xx Oct. 16 at 6:48 PM

$ATXS

0 · Reply

JarvisFlow Oct. 16 at 10:48 AM

HC Wainwright & Co. updates rating for Astria Therapeutics ( $ATXS ) to Neutral.

0 · Reply

anachartanalyst Oct. 15 at 4:02 PM

$ATXS https://anachart.com/wp-content/uploads/ana_temp/1760544139_soc-img.jpg

0 · Reply

JarvisFlow Oct. 15 at 3:15 PM

Wedbush has adjusted their stance on Astria Therapeutics ( $ATXS ), setting the rating to Neutral with a target price of 28 → 13.

0 · Reply

ZacksResearch Oct. 15 at 2:40 PM

$ATXS rockets 37.1% on Tuesday after BioCryst buyout news! BioCryst is set to acquire Astria for a mix of cash and stock, representing a 53% premium, aiming to strengthen its HAE market position with Astria’s promising navenibart therapy. This strategic move is expected to enhance BioCryst’s growth over the next decade. Discover the full acquisition scoop here 👉 https://www.zacks.com/stock/news/2769310/astria-therapeutics-stock-rallies-37-on-700m-buyout-offer-from-bcrx?cid=sm-stocktwits-2-2769310-body-16167&ADID=SYND_STOCKTWITS_TWEET_2_2769310_BODY_16167

0 · Reply

ZacksResearch Oct. 15 at 1:30 PM

$ATXS surges 37% on $700M buyout deal BioCryst’s cash-and-stock offer strengthens its HAE treatment pipeline — a strategic grab that’s clearly energizing the market. Full merger details and what it means for investors 👉 https://www.zacks.com/stock/news/2769310/astria-therapeutics-stock-rallies-37-on-700m-buyout-offer-from-bcrx?cid=sm-stocktwits-2-2769310-teaser-16135&ADID=SYND_STOCKTWITS_TWEET_2_2769310_TEASER_16135

0 · Reply

Market Cap	367.39M
Revenue (ttm)	0.00
Net Income (ttm)	-94.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	235,500
Avg Vol	274,958
Day's Range	N/A - N/A
Shares Out	56.44M
Stochastic %K	10%
Beta	0.48
Analysts	Strong Sell
Price Target	$29.33